FDA rejects Public Citizen's demand to pull Meridia

Public Citizen has lost a three-year battle to persuade the FDA to remove Abbott Laboratories' weight-loss drug Meridia from the market. Regulators said that the drug's benefits continue to outweigh the risks of taking it. Public Citizen maintained that Meridia was linked to more than 400 adverse reactions and contributed to the deaths of dozens of patients. "This decision is good news for obese patients and their physicians who are considering pharmacotherapy who may have been alarmed by Public Citizen," said Dr. John Leonard, Abbott's vice president of global medical affairs.

- read this story from the Chicago Tribune for more

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.